PT - JOURNAL ARTICLE AU - Egon A. Ozer AU - Lacy M. Simons AU - Olubusuyi M. Adewumi AU - Adeola A. Fowotade AU - Ewean C. Omoruyi AU - Johnson A. Adeniji AU - Taylor J. Dean AU - Janet Zayas AU - Pavan P. Bhimalli AU - Michelle K. Ash AU - Adam Godzik AU - Jeffrey R. Schneider AU - João I. Mamede AU - Babafemi O. Taiwo AU - Judd F. Hultquist AU - Ramon Lorenzo-Redondo TI - Coincident rapid expansion of two SARS-CoV-2 lineages with enhanced infectivity in Nigeria AID - 10.1101/2021.04.09.21255206 DP - 2021 Jan 01 TA - medRxiv PG - 2021.04.09.21255206 4099 - http://medrxiv.org/content/early/2021/07/02/2021.04.09.21255206.short 4100 - http://medrxiv.org/content/early/2021/07/02/2021.04.09.21255206.full AB - The emergence of new SARS-CoV-2 variants with enhanced transmissibility or decreased susceptibility to immune responses is a major threat to global efforts to end the coronavirus disease 2019 (COVID-19) pandemic. Disparities in viral genomic surveillance capabilities and efforts have resulted in gaps in our understanding of the viral population dynamics across the globe. Nigeria, despite having the largest population of any nation in Africa, has had relatively little SARS-CoV-2 sequence data made publicly available. Here we report the whole-genome sequences of 74 SARS-CoV-2 isolates collected from individuals in Oyo State, Nigeria in January 2021. Most isolates belonged to either the B.1.1.7 Alpha “variant of concern” or the B.1.525 Eta lineage, which is currently considered a “variant of interest” containing multiple spike protein mutations previously associated with enhanced transmissibility and possible immune escape. Nigeria has the highest reported frequency of the B.1.525 lineage globally with phylogenetic characteristics consistent with a recent monophyletic origin and rapid expansion. Spike protein from the B.1.525 lineage displayed both increased infectivity and decreased neutralization by convalescent sera compared to Spike proteins from other clades. These results, along with indications that the virus is outpacing the B.1.1.7 lineage in Nigeria, suggest that the B.1.525 lineage represents another “variant of concern” and further underline the importance of genomic surveillance in undersampled regions across the globe.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was supported in part through the computational resources and staff contributions provided for the Quest high performance computing facility at Northwestern University, which is jointly supported by the Office of the Provost, the Office for Research, and Northwestern University Information Technology. Genome sequencing and analysis was supported by resources and staff at the Center for Pathogen Genomics and Microbial Evolution in the Northwestern University Institute for Global Health. Funding for this work was provided by: a Northwestern Institute for Global Health Catalyzer Research Fund award (R.L.R. and O.M.A.); a Dixon Translational Research Grant made possible by the generous support of the Dixon Family Foundation (E.A.O. and J.F.H.); a COVID-19 Supplemental Research award from the Northwestern Center for Advanced Technologies (NUCATS - J.F.H.); a CTSA supplement to NCATS UL1 TR002389 (J.F.H., E.A.O., R.L.R.); a supplement to the Northwestern University Cancer Center P30 CA060553 (J.F.H.); the Gilead Sciences Research Scholars Program in HIV (J.F.H.); the NIH-supported Third Coast CFAR P30 AI117943 (R.L.R., J.F.H.); NIH grant K22 AI136691 (J.F.H.); NIH grant U19 AI135964 (E.A.O.); NIH grant D43 TW009608 (B.O.T., O.M.A.); NIH Fogarty International Center award D43TW009608 (B.O.T.); NIH grant R35 GM118187 (A.G.) and NIH-NIAID Center for Structural Genomics of Infectious Diseases award HHSN272201700060C (A.G.); and through a generous contribution from the Walder Foundation Foundation’s Chicago Coronavirus Assessment Network (Chicago CAN) Initiative (J.F.H., E.A.O., R.L.R.) and Walder Foundation grant numbers SCI16(J.R.S) and 21-00147(J.R.S.). The authors also acknowledge the Nigeria Center for Disease Control (NCDC) for providing leadership and infrastructure that facilitated collection of samples included in this study. The funding sources had no role in the study design, data collection, analysis, interpretation, or writing of the report.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was reviewed and approved by the National Health Research Ethics Committee of Nigeria (NHREC) with NHREC protocol number NHREC/01/01/2007 and the University of Ibadan/University College Hospital Health Research Ethics Committee (UI/UCH HREC) with protocol number UI/EC/20/0233. Project name: Phylodynamics and molecular epidemiology of SARS-CoV-2 in Nigeria. Samples from convalescent individuals from Nigeria were collected under a study approved by NHREC with NHREC approval number IRB/20/028. Project name: Plasma and PBMC repository to elucidate the immune and cytokine profile of SARS-CoV-2 Infected Nigerians Samples from vaccinated individuals from the USA were collected under a study approved by the Institutional Review Board of Rush University with protocol number 20032502-IRB01. Project name: SARS CoV-2 Pathogenesis, Immunity, and drug Development.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe final 74 complete SARS-CoV-2 genomes were deposited in the publicly available GISAID database (Supplemental Table 1)